Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis

Author(s): Xinjie Lu*.

Journal Name: Current Drug Targets

Volume 20 , Issue 10 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Background: One of the important factors in Low-Density Lipoprotein (LDL) metabolism is the LDL receptor (LDLR) by its capacity to bind and subsequently clear cholesterol derived from LDL (LDL-C) in the circulation. Proprotein Convertase Subtilisin-like Kexin type 9 (PCSK9) is a newly discovered serine protease that destroys LDLR in the liver and thereby controls the levels of LDL in plasma. Inhibition of PCSK9-mediated degradation of LDLR has, therefore, become a novel target for lipid-lowering therapy.

Methods: We review the current understanding of the structure and function of PCSK9 as well as its implications for the treatment of hyperlipidemia and atherosclerosis.

Results: New treatments such as monoclonal antibodies against PCSK9 may be useful agents to lower plasma levels of LDL and hence prevent atherosclerosis.

Conclusion: PCSK9's mechanism of action is not yet fully clarified. However, treatments that target PCSK9 have shown striking early efficacy and promise to improve the lives of countless patients with hyperlipidemia and atherosclerosis.

Keywords: Proprotein convertase subtilisin/kexin type 9 (PCSK9), low-density lipoprotein cholesterol (LDL-C), LDL receptor (LDLR), atherosclerosis, monoclonal antibody, vaccine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [1029 - 1040]
Pages: 12
DOI: 10.2174/1389450120666190214141626
Price: $58

Article Metrics

PDF: 12